Approval Delayed, But Janssen/Legend’s Cilta-Cel May Hit Market Just In Time
BMS/Bluebird’s Abecma Approved But Demand Exceeds Supply
The US FDA has extended the user fee date by three months for the partners’ BCMA-targeting CAR-T therapy but its first-to-market rival is facing manufacturing challenges that limit access to treatment.
